AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Germany have improved the effectiveness of an HIV vaccine based on viral genetic material.
"We have analyzed the influence of codon usage modifications on the expression levels and immunogenicity of DNA vaccines encoding the human immunodeficiency virus type 1 (HIV-1) group-specific antigen (Gag)," explained Ralf Wagner and colleagues at the University of Regensburg's Institute of Molecular Microbiology and the University of Ulm Institute of Medical Microbiology and Immunology.
Improving the efficiency of the gene sequences coding for Gag enhanced the immunogenicity of these vaccines, Wagner and coworkers found.
Vaccine vectors based on the wild-type HIV gag gene surrounded by essential cis-acting elements could effectively induce cellular Gag expression in most animal and human cell lines, they said, but only in the presence of the HIV Rev protein. A vaccine (syngag) with the coding sequence for Gag optimized to the level of "highly expressed mammalian genes" triggered elevated Gag expression in all cell lines tested, even without the presence of Rev.
Intramuscular injection of the syngag vaccine in mice produced more potent CD4[superscript]+ T cell-based immune responses compared with those induced by Rev-dependent vectors, study data showed. However, intradermal administration of either vaccine type produced antibody-based responses with no ...
Source: HighBeam Research, Gag Optimization Improves Immunogenicity.(Brief Article)